Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Government Unveils Four-Chapter Outline for 2026 Honebuto
The Japanese government on June 25 unveiled the outline for its 2026 Basic Policy on Economic and Fiscal Management and Reform (honebuto), which will comprise four chapters covering macroeconomic management, growth strategy, long-term economic sustainability, and FY2027 budget planning. The…
To read the full story
Related Article
- Japan OKs Honebuto, Growth Strategy with Patented Drug Market Goals
July 21, 2026
- Govt Set to Amend Honebuto Draft over Inflation, MFN Language
July 16, 2026
- LDP Lawmakers Renew Calls to Reflect Inflation in Drug Prices
July 8, 2026
- Govt Eyes Honebuto Revisions on Biosimilars, MFN Policy
July 7, 2026
- LDP Lawmakers Seek Separate Drug Pricing Measures for Inflation
July 2, 2026
- Govt’s Honebuto Draft Confirms FY2027 Off-Year Drug Price Revision
July 1, 2026
- Govt to Explore Greater Rewards for Innovative Drugs in Honebuto
June 29, 2026
- Pharma Wages Multi-Front Lobbying amid Push for Leaner Honebuto
June 12, 2026
- Japan Govt Likely to Slim Down Honebuto, but Details Remain Elusive
June 8, 2026
REGULATORY
- CEA Review Group Debates Draft Report, Eyes August 18 Wrap-Up
August 5, 2026
- Outgoing MHLW Pharmacy Chief Eyes AI as Next Frontier for Drug Regulation
August 4, 2026
- Takeda’s Orzeyful Inches Closer to Japan Approval as 1st NT1 Drug
August 4, 2026
- MHLW Gives Fuel Priority to Drug Deliveries in Quake-Hit Kumamoto
August 4, 2026
- Unami Tapped as Japan’s New Top Finance Bureaucrat
August 3, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…